A phase II randomized placebo-controlled trial of omega-3 fatty acids for the treatment of acute lung injury - Wikidata - awgldk - TriplyDB

A phase II randomized placebo-controlled trial of omega-3 fatty acids for the treatment of acute lung injury

A phase II randomized placebo-controlled trial of omega-3 fatty acids for the treatment of acute lung injury

http://www.wikidata.org/entity/Q30501707

about

Immunonutrition for acute respiratory distress syndrome (ARDS) in adults The Role of Omega-3 Polyunsaturated Fatty Acids in the Treatment of Patients with Acute Respiratory Distress Syndrome: A Clinical Review n-3 fatty acids, γ-linolenic acid, and antioxidants in sepsis Role for phospholipid acyl chains and cholesterol in pulmonary infections and inflammation Salvianolic acid B attenuates lipopolysaccharide-induced acute lung injury in rats through inhibition of apoptosis, oxidative stress and inflammation.Inflammation and immune-related candidate gene associations with acute lung injury susceptibility and severity: a validation study.Obesity and nutrition in acute respiratory distress syndrome.Is omega-3 fatty acids enriched nutrition support safe for critical ill patients? A systematic review and meta-analysis.Tidal volume and plateau pressure use for acute lung injury from 2000 to present: a systematic literature review Interleukin-17A Is Associated With Alveolar Inflammation and Poor Outcomes in Acute Respiratory Distress Syndrome.Supplementation of parenteral nutrition with fish oil attenuates acute lung injury in a rat model.Clinical year in review II: mechanical ventilation, acute respiratory distress syndrome, critical care, and lung cancer.When does nutrition impact respiratory function?The Canadian critical care nutrition guidelines in 2013: an update on current recommendations and implementation strategies.Biomarkers of fish oil omega-3 polyunsaturated fatty acids intake in humans.Enteral omega-3 fatty acid supplementation in adult patients with acute respiratory distress syndrome: a systematic review of randomized controlled trials with meta-analysis and trial sequential analysis.A Matter of Fat.Modulation of Dietary Lipid Composition During Acute Respiratory Distress Syndrome: Systematic Review and Meta-Analysis.Emerging drugs for acute lung injury.Disease-specific nutrition therapy: one size does not fit all.High-Fat Feeding Protects Mice From Ventilator-Induced Lung Injury, Via Neutrophil-Independent Mechanisms.Immunomodulation by lipid emulsions in pulmonary inflammation: a randomized controlled trial.Preemptive enteral nutrition enriched with eicosapentaenoic acid, gamma-linolenic acid and antioxidants in severe multiple trauma: a prospective, randomized, double-blind study.The Omega-3 Fatty Acid Docosahexaenoic Acid Modulates Inflammatory Mediator Release in Human Alveolar Cells Exposed to Bronchoalveolar Lavage Fluid of ARDS Patients.The Effect of Omega-3 Fatty Acids on ARDS: A Randomized Double-Blind Study.Immunomodulation by fish-oil containing lipid emulsions in murine acute respiratory distress syndrome Pharmaconutrition: acute fatty acid modulation of circulating cytokines in elderly patients in the ICU.Respiratory hospitalisation of infants supplemented with docosahexaenoic acid as preterm neonates.The monocyte and acute respiratory distress syndrome: implicated, innocent bystander, or awash in research translation?Hyaluronic acid is associated with organ dysfunction in acute respiratory distress syndrome.Maximizing Nutrition Support Practice and Measuring Adherence to Nutrition Support Guidelines in a Canadian Tertiary Care ICU.Peripheral and Alveolar Cell Transcriptional Programs are Distinct in Acute Respiratory Distress Syndrome.Enteral Diet Enriched with ω-3 Fatty Acid Improves Oxygenation After Thoracic Esophagectomy for Cancer: A Randomized Controlled Trial.Cytometry TOF identifies alveolar macrophage subtypes in acute respiratory distress syndrome.Enteral nutrition with omega-3 fatty acids in critically ill septic patients: A randomized double-blinded study

P2860

Q24186756-692C0F9B-D0EC-40A9-ADF0-E5751E5FA44F Q26784479-22DF0B0F-CAB1-4B83-9325-696BC093EEE2 Q27693887-8FFF41D1-7AD3-4F2B-9481-3704B4C0D8DC Q28391857-68B8AD8C-5317-4E38-BCB3-F3205B020355 Q33847444-4FAED164-70F5-4EE2-99ED-35DD5043A76C Q34516108-82CCF27B-D68D-46D8-8D35-3DD0B774478E Q35153892-12F3C86B-1335-499E-8404-A7BBBDCA0191 Q35179684-FDFE3F08-E2D5-48CA-983B-51E8F9616158 Q35220139-22E3F666-06C2-480F-9A44-7DEF422075BC Q36609573-D96A7E2A-8A20-4964-B6D5-8DA407B2B574 Q37627465-FB595C90-091A-4E15-A558-BD0A3FB1A30E Q38048743-6C9765A4-1952-4AE1-BE64-E1F0856F13B1 Q38103490-75282924-20E1-4437-BC8D-E5D3B99A50BC Q38168142-C5048750-4629-4851-9C75-8F2C28F3EC42 Q38171245-A3D4F51C-3FC7-420B-BAC3-EC64DF90072B Q38189978-1B99F5EF-B35E-4E16-AEEE-CEEE4079CF1C Q38297897-FDFC5DC8-A20D-491D-9766-B3D49ED04FF7 Q38308115-4350DDE2-E0E9-4142-9D9D-816501B34476 Q38308143-747222F7-9488-44BC-B8A8-25417B20C730 Q38713104-CB630857-ED20-46E6-8BA3-0175EACAA158 Q40234630-78F4FFE7-AC40-497B-9849-52132258EE0C Q40875324-4EB7F6D5-F136-450C-99FB-B131934AA47F Q41490095-4D5B2FF2-E2A7-4C7B-9C80-5219F102B7BE Q41825469-D424FB10-3486-4098-804A-B62F7E7687F9 Q41826559-356BD9C6-0342-4149-8F02-DEC410F60BC2 Q42718420-DB9E6D8A-92BE-4BAB-B210-DD89321EF629 Q44198452-406FD455-35B1-4EDA-ABA4-8CAF27AEC49E Q44796046-EC0705BD-68D6-449B-9189-D0E6362E690C Q46125002-485A360F-FA1F-4AB7-9C26-3B95BE9C54B4 Q47160070-CD3FE351-3CD7-4259-9AE1-C8DE213C4AF5 Q47249159-A4BBCB8A-7B58-4367-A350-6CDF5AD5C948 Q47833529-683ADC30-0287-4A56-9095-A39E27BA3DDA Q53538444-CFC85006-C9E4-4FFE-8D1B-5D124DE6080B Q55398444-8CC5644B-6A2B-4616-8556-532969027581 Q59134292-61F395AD-8ED8-4753-A18E-B696ED3A63C4

P2860

A phase II randomized placebo-controlled trial of omega-3 fatty acids for the treatment of acute lung injury

http://www.wikidata.org/entity/Q30501707

description

2011 nî lūn-bûn

@nan

2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

A phase II randomized placebo- ...... treatment of acute lung injury

@ast

A phase II randomized placebo- ...... treatment of acute lung injury

@en

type

label

A phase II randomized placebo- ...... treatment of acute lung injury

@ast

A phase II randomized placebo- ...... treatment of acute lung injury

@en

prefLabel

A phase II randomized placebo- ...... treatment of acute lung injury

@ast

A phase II randomized placebo- ...... treatment of acute lung injury

@en

P1433

Q30501707-DE68E98F-D0E8-496D-80C0-C596F018E906

P1476

Q30501707-90AE49D8-AD33-45E1-BFDB-A84FA3A34C01

P2093

Q30501707-0E47A99C-F0D9-46F7-BCCD-24F6CD7CEC7D

Q30501707-17665218-B7D2-4C93-93D1-72719E590081

Q30501707-257384DA-0FD1-45D2-8C60-F04F732029D5

Q30501707-43B23B8F-FB00-45D5-BEF1-5684B0002B9C

Q30501707-4883AB44-8033-4BD9-A91B-FBF364DA7C18

Q30501707-4DB1BEC0-6441-416C-AF5B-30F3CF815E01

Q30501707-4E3AFB07-98DC-4658-B8D5-3A3B594DD2D5

Q30501707-727C2980-B5AA-4CD8-9729-2985C1FBF77C

Q30501707-79EEFF69-0392-460A-B228-7EAA1DBBB271

Q30501707-8DDFE251-2592-476A-AAC1-ED18116370A9

P2860

Q30501707-0261E6D1-C6B9-457D-B4BC-D1714741CB5C

Q30501707-0390D298-59A0-41C2-8904-6591C134E4D8

Q30501707-0B33AB42-8107-41E0-A0FD-6D2803310F75

Q30501707-0DCD263E-1E8C-4536-A9CA-8DA5FDDAE39D

Q30501707-0E9BE078-9A70-439E-AE27-E2A50E9D93FD

Q30501707-115D1C5C-63A5-4214-A06B-9B18B712730A

Q30501707-206B782F-9FEA-4515-9FFE-3461D984D66B

Q30501707-217C4549-254F-4336-A1A6-6832249E48FB

Q30501707-2778B142-187F-4958-89D8-0E11A8E66B4F

Q30501707-29868DAB-144E-42A5-9E33-407F2A89714C

P304

Q30501707-24D9D552-645C-4D38-BEF3-5CDAE79251E6

P31

Q30501707-B65DD99B-E9B9-48FF-A22E-0D9757FA2C6F

P356

Q30501707-26DC2C4B-A939-454F-B0EF-D6B13F8D442E

P407

Q30501707-05B24101-C7F4-40E0-B601-1B36A479A577

P433

Q30501707-8E7013A6-ECAC-4111-8064-D38719CCE9C1

P478

Q30501707-310AA15A-6B04-4643-8670-723694CAAEF2

P50

Q30501707-56152D03-C886-4422-8B77-4B64AB42605C

P577

Q30501707-B058443E-9246-4314-9D66-9756F9C2C8C0

P698

Q30501707-20E2A926-C7A0-4CB5-B3FA-AA5035472CAA

P921

Q30501707-B1754AFD-42FE-4C46-B492-0194CB41167E

Q30501707-D2AF8505-703A-499D-8541-C4B033E3B1F5

Q30501707-DBAD6883-70E9-4059-B87B-3DDAB9B36265

P932

Q30501707-AE98676A-B4BE-4637-A107-10D51DC95269

P356

CCM.0B013E318218669D

P1433

Critical Care Medicine

P1476

A phase II randomized placebo- ...... treatment of acute lung injury

@en

P2093

Avery B Nathens

http://www.w3.org/2001/XMLSchema#string

Daren K Heyland

http://www.w3.org/2001/XMLSchema#string

Ellen Caldwell

http://www.w3.org/2001/XMLSchema#string

J Randall Curtis

http://www.w3.org/2001/XMLSchema#string

John T Ruzinski

http://www.w3.org/2001/XMLSchema#string

Joseph J Crowley

http://www.w3.org/2001/XMLSchema#string

Julie M Martin

http://www.w3.org/2001/XMLSchema#string

Kathryn A Sims

http://www.w3.org/2001/XMLSchema#string

Margaret J Neff

http://www.w3.org/2001/XMLSchema#string

Mark M Wurfel

http://www.w3.org/2001/XMLSchema#string

P2860

Mixed messages: modulation of inflammation and immune responses by prostaglandins and thromboxanes

A simple method for the isolation and purification of total lipides from animal tissues

Early goal-directed therapy in the treatment of severe sepsis and septic shock

Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network

APACHE II: a severity of disease classification system

Incidence and outcomes of acute lung injury

The acute respiratory distress syndrome

Resolution of inflammation: the beginning programs the end

The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination

Lipid mediators in the pathophysiology of critical illness.

P304

1655-1662

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/CCM.0B013E318218669D

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

39

http://www.w3.org/2001/XMLSchema#string

P50

Teal S. Hallstrand

P577

2011-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21423000

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial

P932

3125670

http://www.w3.org/2001/XMLSchema#string